First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA study

PURPOSE: Combining bevacizumab with paclitaxel significantly improves progression-free survival (PFS) versus paclitaxel alone in HER2-negative metastatic breast cancer (MBC). Eribulin is active and tolerable in pretreated MBC. To assess whether eribulin may offer a more tolerable yet effective combi...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Breast
Main Authors: Hardy-Bessard, Anne-Claire, Brocard, Fabien, Clatot, Florian, Lortholary, Alain, You, Benoît, Grenier, Julien, Martin-Babau, Jérôme, Lucas, Brigitte, Meunier, Jérôme, Ferrero, Jean-Marc, Savoye, Aude-Marie, Marti, Adina, Despax, Raymond, Moullet, Isabelle, Emile, George
Formato: Artigo
Idioma:Inglês
Publicado: Elsevier 2020
Assuntos:
Original Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7672314/
https://ncbi.nlm.nih.gov/pubmed/33188992
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.breast.2020.09.011
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares